VRTX Revenue 2026

Annual and quarterly sales data for Vertex Pharmaceuticals Inc

Latest Annual Revenue

$12.00B

2025-12-31

YoY Growth

+8.9%

vs. previous year

4-Year CAGR

5.0%

compound growth

Annual Revenue History

2025-12-31

$12.00B

YoY Growth

+8.9%

2024-12-31

$11.02B

YoY Growth

+0.0%

2024-12-31

$11.02B

YoY Growth

+11.7%

2023-12-31

$9.87B

YoY Growth

+0.0%

2023-12-31

$9.87B

Quarterly Revenue Breakdown

2025-09-30

$3.08B

2025-09-30

$3.08B

2025-06-30

$2.96B

2025-06-30

$2.96B

2025-03-31

$2.77B

2025-03-31

$2.77B

2024-09-30

$2.77B

2024-09-30

$2.77B

Revenue by Segment

Total Revenue$12.00B (100.0%)

Get Full VRTX Financial Analysis

View complete income statements, balance sheets, and AI-powered insights

Frequently Asked Questions

What is VRTX's revenue?

VRTX (Vertex Pharmaceuticals Inc) reported $12.00 billion in revenue for 2025-12-31. This represents a 8.9% increase compared to the previous year.

How much revenue does VRTX make per year?

Vertex Pharmaceuticals Inc generates approximately $12.00 billion in annual revenue based on the most recent fiscal year ending 2025-12-31.

Is VRTX revenue growing?

Yes, VRTX's revenue is growing. The company achieved 8.9% revenue growth year-over-year. Over the past 4 years, revenue has grown at a compound annual growth rate (CAGR) of 5.0%.

What is VRTX's quarterly revenue?

VRTX reported $3.08 billion in revenue for the most recent quarter (2025-09-30).

What are VRTX's revenue sources?

VRTX's revenue comes from multiple segments: Total Revenue. See the revenue breakdown below for detailed segment analysis.

How does VRTX compare to competitors in revenue?

VRTX generates $12.00 billion in annual revenue in the Health Care sector. Compare VRTX to competitors using our stock comparison tool to see relative market share and growth rates.

Disclaimer: Revenue data is based on publicly filed financial statements. Historical performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.

Explore Categories